Table 8.
Analyses of VEGF and IDO expression in the breast tumours in women with LLABCs (pre-NAC and post-NAC) and association with a PCR.
| VEGF/IDO (n = 16) | Groups | Pre-NAC | Post-NAC | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Low/negative expression (n) | High expression (n) | Pearson chi-square value (GPR versus PPR, PCR versus non-PCR) | p value | Low/negative expression (n) | High expression (n) | Pearson chi-square value (GPR versus PPR, PCR versus non-PCR) | p value | ||
| VEGF | Good pathological response (GPR, n = 9) | 5 | 4 | 1.667 | 0.197 | 7 | 2 | 0.780 | 0.377 |
| Poor pathological response (PPR, n = 7) | 6 | 1 | 4 | 3 | |||||
| Pathological complete response (PCR, n = 6) | 2 | 4 | 5.605 | 0.018∗ | 5 | 1 | 0.950 | 0.330 | |
| Nonpathological complete response (non-PCR, n = 10) | 9 | 1 | 6 | 4 | |||||
|
| |||||||||
| IDO | Good pathological response (GPR, n = 9) | 6 | 3 | 0.042 | 0.838 | 6 | 3 | 0.152 | 0.696 |
| Poor pathological response (PPR, n = 7) | 5 | 2 | 4 | 3 | |||||
| Pathological complete response (PCR, n = 6) | 3 | 3 | 1.571 | 0.210 | 4 | 2 | 0.071 | 0.790 | |
| Nonpathological complete response (non-PCR, n = 10) | 8 | 2 | 6 | 4 | |||||
VEGF: vascular endothelial growth factor; IDO: indoleamine 2,3-dioxygenase; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; ∗statistically significant.